AIM Vaccine Valuation

Is 6660 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6660 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6660's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6660's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6660?

Key metric: As 6660 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6660. This is calculated by dividing 6660's market cap by their current revenue.
What is 6660's PS Ratio?
PS Ratio6.5x
SalesCN¥1.18b
Market CapCN¥7.84b

Price to Sales Ratio vs Peers

How does 6660's PS Ratio compare to its peers?

The above table shows the PS ratio for 6660 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.9x
2696 Shanghai Henlius Biotech
2x10.1%HK$12.0b
6855 Ascentage Pharma Group International
13.3x26.6%HK$13.0b
6185 CanSino Biologics
10.2x33.3%HK$12.9b
6955 Shandong Boan Biotechnology
6.3x29.0%HK$5.0b
6660 AIM Vaccine
6.5xn/aHK$8.4b

Price-To-Sales vs Peers: 6660 is good value based on its Price-To-Sales Ratio (6.5x) compared to the peer average (7.9x).


Price to Sales Ratio vs Industry

How does 6660's PS Ratio compare vs other companies in the HK Biotechs Industry?

14 CompaniesPrice / SalesEstimated GrowthMarket Cap
1530 3SBio
1.6x9.5%US$1.92b
6826 Shanghai Haohai Biological Technology
2.2x11.8%US$1.79b
2696 Shanghai Henlius Biotech
2x10.1%US$1.55b
775 CK Life Sciences Int'l. (Holdings)
0.8xn/aUS$531.65m
6660 6.5xIndustry Avg. 11.0xNo. of Companies14PS01632486480+
14 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 6660 is good value based on its Price-To-Sales Ratio (6.5x) compared to the Hong Kong Biotechs industry average (11x).


Price to Sales Ratio vs Fair Ratio

What is 6660's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6660 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6660's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies